|Bid||24.35 x 1400|
|Ask||24.48 x 1000|
|Day's Range||23.09 - 26.27|
|52 Week Range||23.09 - 133.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 13, 2022 - Apr 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.41|
Subscribe to Yahoo Finance Plus to view Fair Value for CVACLearn more
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the company's Chief Technology Officer, Dr.
What happened Shares of vaccine maker CureVac (NASDAQ: CVAC) were sinking 10.8% lower as of 10:43 a.m. ET on Friday. The decline came after investment company dievini and the German government announced the signing of a revised shareholder agreement on Thursday related to their shares in CureVac.
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.